硫堇相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
81	다중 파장에서 발광하는 황화 카드뮴 나노 결정의 제조방법 및 그에 의해 수득된 황화 카드뮴 나노 결정	KR1020040038392	2004-05-28	KR1020050112939A	2005-12-01	장은주; 전신애; 안태경; 이성훈; 최성재
본 발명은 황화 카드뮴 나노 결정의 제조방법 및 그에 의해 수득된 황화 카드뮴 나노 결정에 관한 것으로서, 보다 상세하게는 (a)카드뮴 전구체 및 분산제를 배위력이 약한 용매와 혼합하고, 이를 가열하여 카드뮴 전구체 용액을 얻는 단계; (b)황 전구체를 배위력이 약한 용매에 용해하여 황 전구체 용액을 얻는 단계; 및 (c)상기 가열된 항온의 카드뮴 전구체 용액에 상온의 황 전구체 용액을 주입하여 황화 카드뮴 결정을 성장시키는 단계를 포함하는 황화 카드뮴 나노 결정의 제조방법 및 그에 의해 수득된 황화 카드뮴 나노 결정에 관한 것으로, 본 발명의 제조 방법에 의해 얻어진 황화 카드뮴 나노 결정은 크기와 형태가 균일하고 에너지 여기 시에 여러 파장에서 동시에 발광하여 백색에 가까운 빛을 내는 특성을 가지며 이를 백색 발광 다이오드 소자에 응용할 수 있다.
82	Insecticidal N-carbamoyl-oxadiazolidin-5-ones and thiones	US514073	1983-07-15	US4499098A	1985-02-12	Laroy H. Edwards
Compounds of the formula: ##STR1## wherein X is oxygen or sulfur; R.sup.1 and R.sup.2 are independently lower alkyl having from 1 to 4 carbon atoms; and R.sup.3 is lower alkyl having from 1 to 6 carbon atoms, lower cycloalkyl having from 3 to 6 carbon atoms optionally substituted with methyl or ethyl, lower alkoxyalkyl having up to a total of 8 carbon atoms or lower alkylthioalkyl having up to a total of 8 carbon atoms are insecticidal.
83	Oxiranyl-triazoline thiones and their use as microbicides	US82705801	2001-04-05	US6414007B2	2002-07-02	HILLEBRAND STEFAN; JAUTELAT MANFRED; MAULER-MACHNIK ASTRID; STENZEL KLAUS; KUGLER MARTIN; EXNER OTTO
Novel oxiranyl-triazolinethiones of the formulain whichR1, R2 and R3 are each as defined in the description,a process for preparing the novel substances and their use as microbicides in crop protection and in the protection of materials.
84	Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases	US09382960	1999-08-25	US06365616B1	2002-04-02	Leonard D. Kohn; Robert W. Curley; John M. Rice
The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. These methods utilize specifically-defined methimazole derivatives and tautomeric cyclic thione compounds, as well as pharmaceutical compositions containing those compounds. These compounds and compositions have been found to be at least as effective as methimazole in terms of pharmaceutical activity, while having less of an adverse affect on thyroid function. They are also more soluble in conventional pharmaceutical vehicles than methimazole. An assay for screening the activity of compounds useful against autoimmune diseases (ability to suppress expression of MHC Class I and II molecules) is also taught.
85	스트론튬 옥시오소실리케이트 형광체 유형에서 방사 부하에 대한 안정성 및 대기 습도의 영향에 대한 내성을 향상시키기 위한 수단	KR1020100039545	2010-04-28	KR1020110073186A	2011-06-29	이정훈; 튜스,월터; 군둘라로스; 데트레프스타릭
PURPOSE: A phosphor is provided to improve stability to radiation load and resistance to the influence of atmospheric humidity. CONSTITUTION: A unit for improving stability to radiation load and resistance to the influence of atmospheric humidity in strontium oxyorthosilicate phosphors is added as silicate phosphors of chemical formula: Sr_(3-x-y-z)Ca_xM^II_ySiO_5 : Eu_z having calcium molar fraction x between 0-0.05. In chemical formula, a europium molar fraction z is the value of a range of <=0.25; and M^II is divalent metallic ion selected from the group consisting of agnesium, barium, copper, zinc and manganese.
86	SULFATED PSYLLIUM DERIVATIVE FOR REDUCING THE RISK OF CHRONIC HUMAN DISEASES AND METHOD FOR PREPARING THE SAME	US12847747	2010-07-30	US20110054207A1	2011-03-03	LIANGLI YU; WEI LIU; ZHOUHONG XIE; QIN WANG; BOCE ZHANG
The invention is directed to a method for preparing sulfated psyllium derivatives for use to reduce the risk of chronic human diseases. The sulfation of psyllium was carried out with sulfur, trioxide, pyridine, dimethylformamide and chlorosulfonic acid in pyridine. Six total sulfated psyllium derivatives named SP1, SP2, SP3, SPR1, SPR2, and SPR3 were prepared and evaluated for their morphological and rheological properties, and bile acid-binding abilities. The invention offers a novel approach to obtaining sulfated psyllium derivatives for use in functional foods or supplemental and pharmaceutical products to increase health benefits.
87	Ettringite binder for dense mortar, comprising calcium sulphates and a mineral compound of calcium aluminates	US10512347	2003-04-24	US07208040B2	2007-04-24	Loris Amathieu; Bruno Touzo
The invention relates to an ettringite binder for dense mortar, comprising calcium sulphates and a calcium aluminate mineral compound, the calcium aluminate mineral compound comprising calcium C and aluminum A oxides, soluble and combined in one or more crystallized and/or amorphous mineralogical phases, in such proportions that: the useful C/A molar ratio of the calcium aluminate mineral compound ranges from 1.2 to 2.7; the sum in weight of the useful (C+A) phases accounts for at least 30% of the total weight of the mineral compound.
88	Ettringite binder for dense mortar, comprising calcium sulphates and a mineral compound of calcium aluminates	US10512347	2003-04-24	US20060118006A1	2006-06-08	Loris Amathieu; Bruno Touzo
The invention relates to an ettringite binder for dense mortar, comprising calcium sulphates and a calcium aluminate mineral compound, the calcium aluminate mineral compound comprising calcium C and aluminum A oxides, soluble and combined in one or more crystallized and/or amorphous mineralogical phases, in such proportions that: the useful C/A molar ratio of the calcium aluminate mineral compound ranges from 1.2 to 2.7; the sum in weight of the useful (C+A) phases accounts for at least 30% of the total weight of the mineral compound.
89	Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)	US11391675	2006-03-29	US20060287523A1	2006-12-21	Claude Wischik; Janet Rickard; Charles Harrington; David Horsley; John Storey; Colin Marshall; James Sinclair; Han Tan
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diaminophenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.
90	Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)	US11575845	2005-09-21	US07790881B2	2010-09-07	John Mervyn David Storey; James Peter Sinclair; Colin Marshall; Han Wan Tan
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. Wherein: each of R1 and R9 is independently selected from: —H; C1-4 alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: C1-4 alkyl; C2-4alkenyl; and halogenated C4-1 alkyl; each of R7NA and R7NB is independently selected from: C1-4 alkyl; C2-4alkenyl; and halogenated C1-4 alkyl; and X is one or more anionic counter ions to achieve electrical neutrality.
91	Substituted 4,5-dihydroxy-imidazolidine-2-thiones and their use as ectoparasiticides	US858917	1977-12-08	US4173645A	1979-11-06	Edgar Enders; Volker Ebbighausen; Wolfgang Gau; Christian Wunsche; Wilhelm Stendel
The present invention provides, as compounds, the substituted 4,5-dihydroxy-imidazolidine-2-thiones of the general formula ##STR1## in which R.sup.1, R.sup.2 and R.sup.3, which are selected independently of one another each represent hydrogen, optionally substituted alkyl, optionally substituted alkoxy or halogen andR.sup.4 represents optionally substituted alkyl, cycloalkyl or alkenyl.It has been found that the compounds of this invention have a powerful ectoparasiticidal action, in particular against acarids.
92	Combating insects and mites with 1-carbamyl-4H-1,2,4-triazolin-5-ones and thiones	US660090	1976-02-23	US4070474A	1978-01-24	Joel L. Kirkpatrick
Insects and mites are combated by applying to the locus of insects in at least one stage of the insects' life cycle an effective amount of a compound having the structural formula ##STR1## in which X and X' may be oxygen or sulfur, R may be alkyl, cycloalkyl, aryl, alkenyl, alkynyl, optionally substituted with halogen, hydroxy, alkoxy, nitro, mercapto or alkylthio substituents, R' may be hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl etc., and if R' is not hydrogen one of R" and R"' may be hydrogen while one or both may be alkyl, optionally substituted with halogen, hydroxy, alkoxy, mercapto or alkylthio substituents or R" and R"' together may be part of a heterocyclic ring containing 2 to 6 carbon atoms, with the provision that the total of R, R', R" and R"', must contain from 4 to 13 carbon atoms and if R is straight chain alkyl having less than 6 carbon atoms, none of R', R" and R"' may be hydrogen. The novel insecticides are particularly useful in combating aphids.
93	Pyrido[2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and thiones and their use on the treatment of HIV infection	US292123	1994-08-17	US5550122A	1996-08-27	Karl D. Hargrave; Gunther Schmidt, deceased
Disclosed are pyrido[2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones. These are useful in the prevention or treatment of AIDS.
94	Dibenz[b,f][1,4]oxazepin(and thiazepin)-11(10H)-ones and-thiones and their use in the prevention or treatment of HIV infection	US271350	1994-07-06	US5571806A	1996-11-05	Karl D. Hargrave; Gunther Schmidt, deceased; Wolfhard Engel; Kurt Schromm
Disclosed is the use of dibenz[b,f][1,4]oxazepin (or thiazepin)-11(10H)-ones and -thiones in the prevention and treatment of AIDS, ARC and related disorders associated with HIV infection.
95	METHOD OF PREPARING CADMIUM SULFIDE NANOCRYSTALS EMITTING LIGHT AT MULTIPLE WAVELENGTHS, AND CADMIUM SULFIDE NANOCRYSTALS PREPARED BY THE METHOD	US12496243	2009-07-01	US20090267050A1	2009-10-29	Eun Joo JANG; Shin Ae JUN; Tae Kyung AHN; Sung Hun LEE; Seong Jae CHOI
A cadmium sulfide nanocrystal, wherein the cadmium sulfide nanocrystal shows maximum luminescence peaks at two or more wavelengths and most of the atoms constituting the nanocrystal are present at the surface of the nanocrystal to form defects.
96	Small and cysteine rich antifungal defensin and thionine-like protein genes highly expressed in the incompatible interaction	US09442631	1999-11-18	US06300489B1	2001-10-09	Boung-Jun Oh; Moon Kyung Ko; Byongchul Shin
The present invention related to two cDNA clones, designated to PepDef (pepper defensin protein gene) and PepThi (pepper thionin-like protein gene) and individual component; thereof including its coding region and its gene product; modification thereto; application of said gene, coding region and modification thereto; DNA construct, vectors and transformed plants each comprising the gene or part thereof.
97	Method for producing cadmium sulfide nano-crystal emitting light with multiwavelengths, cadmium sulfide nano-crystal produced by the same, and white light emitting diode element	JP2005157791	2005-05-30	JP2005336052A	2005-12-08	CHO GINSHU; JUN SHIN AE; LEE SUNG-HOON; SAI SEISAI; AHN TAE-KYUNG
PROBLEM TO BE SOLVED: To provide a method for producing a cadmium sulfide nano-crystal emitting light with multiwavelengths, the cadmium sulfide nano-crystal produced by the same, and a white light emitting diode element using the same. SOLUTION: The method for producing the semiconductor cadmium sulfide nano-crystal comprises of a step obtaining a cadmium precursor solution by mixing a cadmium precursor and a dispersing agent with a solvent having a weak coordination power and heating the resulting mixture, a step of obtaining a sulfur precursor solution by dissolving a sulfur precursor in a solvent having a weak coordination power, and a step of growing the cadmium sulfide crystal by injecting the sulfur precursor solution into the heated cadmium precursor solution. COPYRIGHT: (C)2006,JPO&NCIPI
98	Psychoactive 1,3,4-benzotriazepine-2-thiones and a method for treating central nervous system depression and anxiety	US877064	1978-02-13	US4194000A	1980-03-18	Donald L. Trepanier; Thomas C. Britton
Novel 1,3,4-benzotriazepine-2-thiones and related tricyclic derivatives having central nervous system activity and a method of use for treating the symptoms of central nervous system depression and anxiety.
99	Psychoactive 1,3,4-benzotriazepine-2-thiones and a method for treating central nervous system depression and anxiety	US877063	1978-02-13	US4168310A	1979-09-18	Donald L. Trepanier; Thomas C. Britton
Novel 1,3,4-benzotriazepine-2-thiones and related tricyclic derivatives having central nervous system activity and a method for use for treating the symptoms of central nervous system depression and anxiety.
100	Reaction bonded ceramics for ceramic composite materials comprising mullite as the main component and corundum and thortveitite or cerianite as minor components	US873129	1997-06-11	US6083861A	2000-07-04	Bilge Saruhan; Peter Mechnich; Hartmut Schneider
Reaction Bonded Ceramics for Ceramic Composite Materials Comprising Mullite as the Main Component and Corundum and Thortveitite or Cerianite as Minor ComponentsThe present invention pertains to reaction bonded mullite-containing ceramic molded parts, a process for their preparation and their use.A particular embodiment of the present invention consists in reaction bonded mullite-containing ceramic molded parts, obtainable by the heat-treatment of a finely dispersed mixture of an aluminum-containing material, a silicon-containing material, and a rare earth metal-containing material in an oxygen-containing atmosphere.

1 2 3 4 5 6 7 8 9 10

IPRDB

热门服务

关于我们

友情链接

联系方式